Drug Trial Radar · NCT02257918
Randomized, Open-label Phase 2 Study of Oral AZD0914 in the Treatment of Gonorrhea
Last checked: Nov 20, 2026Latest source record: Mar 22, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Nov 25, 2014
Primary completion
Dec 30, 2015
Study completion Dec 30, 2015
Sponsor
- Sponsor type
- NIH
- First posted
- Oct 7, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center Phase 2 randomized, open-label study in approximately 180 adult male and female subjects, between the ages of 18 and 55, who are in good health and meet all eligibility criteria. The study is designed to assess the safety and efficacy of an antimicrobial investigational product, AZD0914 manufactured by AstraZeneca, administered to adults to treat uncomplicated urogenital gonorrhea compared to treatment with ceftriaxone. Subjects will be randomly assigned 70:70:40 to receive a single, oral dose of 2000 mg of AZD0914, 3000 mg of AZD0914, or intramuscular dose of 500 mg of ceftriaxone. The drug name is also known as ETX0914.
Conditions
- Gonorrhoea
Interventions
AZD0914Drug
AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
CeftriaxoneDrug
Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Microbiological Cure at Urethral or Cervical Sites in Each Study ArmTime frame: Day 6
- Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs) Considered Product-related.Time frame: Day 1 through Day 31
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Jefferson County Department of Health - STD Clinic
Birmingham, Alabama
Indiana University - Bell Flower Clinic
Indianapolis, Indiana
CrescentCare Health and Wellness Center
New Orleans, Louisiana
Durham County Health Department
Durham, North Carolina
Public Health STD Clinic
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.